Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | MB | P02144 | 1/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11201779 | 0.90 | POLB (0.50) | AOC3SMN1; SMN2HTTL3MBTL1ALDH1A1 | |
| SCHEMBL29622963 | 0.85 | AOC3 (0.67) | AOC3SMN1; SMN2HTTL3MBTL1ALDH1A1 | |
| SCHEMBL29622962 | 0.85 | AOC3 (0.67) | AOC3SMN1; SMN2HTTL3MBTL1ALDH1A1 | |
| SCHEMBL7771746 | 0.81 | TSHR (0.59) | SMN1; SMN2HTTL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL11116153 | 0.81 | SMN1; SMN2 (0.59) | AOC3SMN1; SMN2HTTL3MBTL1ALDH1A1 | |
| SCHEMBL1902060 | 0.81 | SMN1; SMN2 (0.59) | AOC3SMN1; SMN2HTTL3MBTL1ALDH1A1 | |
| SCHEMBL7211903 | 0.79 | AOC3 (0.61) | AOC3SMN1; SMN2HTTL3MBTL1ALDH1A1 | |
| SCHEMBL8868289 | 0.79 | SMN1; SMN2 (0.57) | AOC3SMN1; SMN2HTTL3MBTL1ALDH1A1 | |
| SCHEMBL6629816 | 0.79 | SMN1; SMN2 (0.57) | AOC3SMN1; SMN2HTTL3MBTL1ALDH1A1 | |
| SCHEMBL8681807 | 0.79 | SMN1; SMN2 (0.57) | AOC3SMN1; SMN2HTTL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4727079-A | Brain-specific dopaminergic activity involving dihydropyridine carboxamides, dihydroquinoline and isoquinoline carboxamides | UNIVERSITY OF FLORIDA (US) | 1988-02-23 | — | — | US | claimed |
| EP-3219717-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (R)-N-METHYLNALTREXONE | Progenics Pharmaceuticals, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20170143700-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | PROGENICS PHARMACEUTICALS, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9597327-B2 | Synthesis of (R)-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150290187-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | Progenics Pharmaceuticals., Inc. | 2015-10-15 | — | — | US | disclosed |
| US-20150057303-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | PROGENICS PHARMACEUTICALS, INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-20130323286-A1 | SYNTHESIS OF R-N-METHYLNALTREXONE | PROGENICS PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-8343992-B2 | Synthesis of R-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| EP-2450359-A2 | (R)-N-Methylnaltrexone | Progenics Pharmaceuticals, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20100311781-A1 | SYNTHESIS OF R-N-METHYLNALTREXONE | PROGENICS PHARMACEUTICALS, INC. | 2010-12-09 | — | — | US | disclosed |
| EP-0036426-A1 | NOVEL PROCESS AND INTERMEDIATES USEFUL IN THE PREPARATION OF SYMPATHOMIMETIC AMINES. | INTERX RESEARCH CORP (US) | 1981-09-30 | — | — | EP | disclosed |
| US-4285947-A | DIURETICS, HYPOTENSIVES | INTERX RESEARCH CORPORATION (US) | 1981-08-25 | — | — | US | disclosed |
| EP-0032725-A1 | Novel aldehyde adducts of triamterene and a pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1981-07-29 | — | — | EP | disclosed |
| US-4275219-A | Novel process and intermediates useful in the preparation of sympathomimetic amines | INTERX RESEARCH CORPORATION (US) | 1981-06-23 | — | — | US | disclosed |
| WO-1981000849-A1 | NOVEL PROCESS AND INTERMEDIATES USEFUL IN THE PREPARATION OF SYMPATHOMIMETIC AMINES | INTERX RESEARCH CORP (US) | 1981-04-02 | — | — | WO | disclosed |
| US-RE30241-E | BRONCHODILATION, ADRENERGIC STIMULANTS | STERLING DRUG INC. (US) | 1980-03-25 | — | — | US | disclosed |
| US-4145441-A | SYMPATHOMIMETIC AMINES EXHIBITING ANTI-HEMORRHOIDAL ACTIVITY | INTERX RESEARCH CORPORATION (US) | 1979-03-20 | — | — | US | disclosed |
| US-4138581-A | BRONCHODILATOR AGENTS, ADRENERGIC STIMULANTS | STERLING DRUGS INC. (US) | 1979-02-06 | — | — | US | disclosed |
| US-4094983-A | \"KETO\" SYMPATHOMIMETIC AMINES | INTERX RESEARCH CORPORATION (US) | 1978-06-13 | — | — | US | disclosed |
| US-4035405-A | Novel synthesis for preparing the hydrochloride salt of selected catecholamine derivatives | INTERX RESEARCH CORPORATION (US) | 1977-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130323286-A1 | SYNTHESIS OF R-N-METHYLNALTREXONE | OPRM1, OPRK1, OPRL1 | AOC3 3155/4885SMN1; SMN2 233/4885HTT 1540/4885 |
| US-20170143700-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | OPRM1, OPRL1, OPRK1 | AOC3 2921/4885SMN1; SMN2 217/4885HTT 1411/4885 |
| US-20150057303-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | OPRM1, OPRL1, OPRK1 | AOC3 2921/4885SMN1; SMN2 217/4885HTT 1411/4885 |
| US-20100311781-A1 | SYNTHESIS OF R-N-METHYLNALTREXONE | OPRM1, OPRK1, OPRL1 | AOC3 3155/4885SMN1; SMN2 233/4885HTT 1540/4885 |
| US-20150290187-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | OPRM1, OPRL1, OPRK1 | AOC3 2921/4885SMN1; SMN2 217/4885HTT 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.